'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. What Happened: On Saturday, in a post on X, Shkreli forecasted a potential 90% drop in the shares of biotech startup, Inmune Bio Inc. INMB, a clinical-stage biotechnology company that is focused on using a patient’s immune system to fight cancers.According to Shkreli, there’s a “very good chance $INMB will be at 0.50 on Monday,” a 90.61% drop from its cl ...